CSS
SYRS

Cubist Systematic Strategies’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Cubist Systematic Strategies’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-595
Closed -$1.28K – 3673
2024
Q3 		$1.28K Sell
595
-3,285
-85% -$11.8K ﹤0.01% 2892
2024
Q2 		$20K Buy
+3,880
New +$20.4K ﹤0.01% 2768
2022
Q3 		– Sell
-1,128
Closed -$11K – 4798
2022
Q2 		$11K Sell
1,128
-927
-45% -$8.67K ﹤0.01% 4263
2022
Q1 		$24K Sell
2,055
-477
-19% -$8.53K ﹤0.01% 3466
2021
Q4 		$83K Sell
2,532
-6,167
-71% -$250K ﹤0.01% 3236
2021
Q3 		$389K Sell
8,699
-17,101
-66% -$835K ﹤0.01% 2196
2021
Q2 		$1.41M Buy
25,800
+23,197
+891% +$1.37M 0.02% 1335
2021
Q1 		$195K Sell
2,603
-1,208
-32% -$125K ﹤0.01% 2488
2020
Q4 		$414K Buy
3,811
+2,956
+346% +$270K 0.01% 1874
2020
Q3 		$76K Sell
855
-1,053
-55% -$120K ﹤0.01% 2326
2020
Q2 		$203K Buy
1,908
+1,891
+11,124% +$170K ﹤0.01% 2025
2020
Q1 		$1K Buy
+17
New +$1.15K ﹤0.01% 2124
2019
Q1 		– Sell
-53
Closed -$3K – 2453
2018
Q4 		$3K Sell
53
-137
-72% -$10.4K ﹤0.01% 2006
2018
Q3 		$23K Sell
190
-977
-84% -$113K ﹤0.01% 1780
2018
Q2 		$119K Buy
+1,167
New +$145K 0.01% 1487
2017
Q4 		– Sell
-1,013
Closed -$149K – 2132
2017
Q3 		$149K Buy
+1,013
New +$191K 0.01% 1544

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Cubist Systematic Strategies's SYRS Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 595 shares — an estimated $1.28K sold.

Cubist Systematic Strategies first reported a position in SYRS in Q3 2017 and held it in 16 quarters. The position peaked at $1.41M in Q2 2021. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 595 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.28K.
  • Cubist Systematic Strategies first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 16 quarters.
  • Cubist Systematic Strategies's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.41M in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.